N/A N=491 Vistakon Investigational Contact Lenses Worn for Daily Wear
Myopia
Primary: Slit Lamp Findings — 7; 2 Number of Subject Eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=475 Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33
N/A N=600 Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice
Osteoporosis, Postmenopausal
Primary: Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office — 295; 296 participants
Phase 4 N=135 Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy
Procedural Sedation
Primary: Level of Sedation Throughout the Entire Procedure — 22; 9; 10; 1 participants
N/A N=148 Pending Failure in Hard-hard Total Hip Arthroplasty
Infection and Inflammatory Reaction
Primary: Number of Participants With Chromium and Cobalt Ion Levels Above 7ug/l — 14; 0 participants above limit
Phase 2 N=99 Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Advanced Breast Cancer
Primary: Number of Participants With Disease Progression (PD) or Death — 35; 40 participants
Phase 3 N=381 Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Primary Disease
Primary: Average Adjusted Symptom Score (AAdSS) — 5.58; 6.07 Units on a scale (range: 0 to 18) — p=0.2344
Phase 2 N=265 Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Phase 1 N=30 Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
Advanced Solid Malignancy, · Safety and Tolerability, · Pharmacokinetics, Pharmacodynamics,
Primary: Ratio of Css,Max for Day 4 to Day 11 — 1.02; 0.67 Ratio
Phase 2 N=42 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Liposarcoma · Surgically Unresectable Liposarcoma · Metastatic Liposarcoma
Primary: 12-week Progression Free Rate — 68.29 percentage of participants
Phase 2 N=65 Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting — 29.6; 46.3; 24.1 percentage of participants
Phase 2 N=26 Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Dose-limiting Toxicity (DLT) (Phase I) — 0; 0; 0; 0 participants
Phase 3 N=633 Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
Allergy
Primary: Average Adjusted Symptom Score (AAdSS) — 3.39; 3.25; 5.21 Units on a scale (range: 0 to 18) — p=< 0.0001
N/A N=547 A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
Osteoarthritis
Primary: Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® — 65; 118 Participants
Phase 3 N=603 A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Anemia
Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036